Prothena Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
676.00
50,854.00
1,607.00
1,055.00
27,519.00
955
SG&A Expense
40,443.00
56,760.00
80,738.00
158,163.00
179,706.00
140,449
EBIT
40,427.00
6,649.00
79,937.00
159,535.00
155,254.00
142,710
Non Operating Income/Expense
225.00
231.00
170.00
15.00
5,895.00
3,649
Pretax Income
40,581.00
6,339.00
79,911.00
158,964.00
157,603.00
156,115
Income Tax
415.00
811.00
701.00
1,144.00
4,366.00
470
Consolidated Net Income
40,996.00
7,150.00
80,612.00
160,108.00
153,237.00
155,645
Net Income
40,996.00
7,150.00
80,612.00
160,108.00
153,237.00
155,645
Net Income After Extraordinaries
40,996.00
7,150.00
80,612.00
160,108.00
153,237.00
155,645
Net Income Available to Common
40,996.00
7,150.00
80,612.00
160,108.00
153,237.00
155,645
EPS (Basic)
2.20
0.29
2.66
4.66
4.07
3.93
Basic Shares Outstanding
18,615.00
24,672.00
30,326.00
34,351.00
37,654.00
39,559
EPS (Diluted)
2.20
0.29
2.66
4.66
4.07
3.93
Diluted Shares Outstanding
18,615.00
24,672.00
30,326.00
34,351.00
37,654.00
39,559
EBITDA
39,767.00
5,906.00
79,131.00
157,108.00
152,187.00
139,494
Non-Operating Interest Income
71.00
79.00
196.00
556.00
3,546.00
6,389

About Prothena

View Profile
Address
77 Sir John Rogersons Quay
Dun Laoghaire Dublin 2
Ireland
Employees -
Website http://www.prothena.com
Updated 07/08/2019
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded on December 20, 2012 and is headquartered in Dun Laoghaire, Ireland.